Journal of Infection and Chemotherapy最新文献

{"title":"Effectiveness of immunoprophylaxis for preterm infants of mothers having chronic hepatitis B virus infection: A retrospective study","authors":"Guanlun Zhou ,&nbsp;Qiao Yan ,&nbsp;Wenjing Yu ,&nbsp;Chao Chen ,&nbsp;Hongxiu Jiang ,&nbsp;Minkai Cao ,&nbsp;Yan Chen ,&nbsp;Guorong Han","doi":"10.1016/j.jiac.2025.102680","DOIUrl":"10.1016/j.jiac.2025.102680","url":null,"abstract":"<div><h3>Background</h3><div>The effectiveness of immunoprophylaxis for preterm infants delivered by hepatitis B virus(HBV)-infected mothers remains unclear. This study aimed to investigate the effectiveness of immunoprophylaxis in preterm infants.</div></div><div><h3>Methods</h3><div>Infants delivered by HBV-infected mothers between January 1, 2016 and December 31, 2018 were enrolled, Preterm infants received hepatitis B vaccine immediately after birth and at one, two and seven months while full-term infants received vaccine immediately after birth and at one and six months. All infants were followed utill 24 months. Effectiveness of immunoprophylaxis in preterm infants was analyzed by comparing the dynamics of HBV markers and responsible factors were investigated using multivariate regression analysis.</div></div><div><h3>Results</h3><div>During the study period (2016–2018), 2238 infants were enrolled, including 175 preterm infants and 2063 full-term infants. The differences in the HBsAb concentration between groups were not statistically significant at 7–12 and 24 months of age (P &gt; 0.05), but the concentration in the preterm group were lower relative to the full-term group. Apgar score at 1 min was a predictor of medium-to-high response of HBsAb at 7–12 month (OR 2.687, P = 0.027).</div></div><div><h3>Conclusions</h3><div>HBsAb concentration in preterm infants delivered by HBV-infected mothers who were vaccinated following the \"0-1-2-7″ protocol were similar to those in full-term infants, thereby indicating good outcomes. One-minute Apgar score could be used to predict HBsAb levels in preterm infants at 7–12 months of age after completion of the immunoprophylaxis.</div></div>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":"31 4","pages":"Article 102680"},"PeriodicalIF":1.9,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143715482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transition of yellow fever immunization environment in Japan","authors":"Kenji Gotoh ,&nbsp;Kazuhiro Kakimoto","doi":"10.1016/j.jiac.2025.102685","DOIUrl":"10.1016/j.jiac.2025.102685","url":null,"abstract":"<div><div>Before the approval of one-dose vaccine vials against yellow fever in 2019, the vaccination and an international certificate of vaccination were provided mostly at quarantine stations in Japan. In those days, only five-dose vaccine vials were approved by the government, and were not beneficial for travel clinics in hospital because they needed to collect enough vaccine recipients to avoid waste of the vaccine in the vial. Since one-dose vaccine vials were approved in 2019, several travel clinics in hospital became interested in administrating the vaccine at travel clinics in hospital. The hospital-based yellow fever vaccination is an extremely beneficial environment for pre-travel medical care such as simultaneous vaccination with other vaccines, prompt response to anaphylaxis, prescriptions for malaria prophylaxis and altitude sickness prophylaxis in the same place. However, the travel clinics in hospital which want to start the vaccination against yellow fever need to be certified by the Ministry of Health, Labour and Welfare after receiving mobile vaccination by a quarantine station for about two years. As of December 2024, in addition to 6 quarantine stations, 14 travel clinics were certified and able to provide yellow fever vaccination and an international certificate as well as other pre-travel medical care. In the future, the number of travel clinics in Japan that can administer yellow fever vaccination is expected to further expand.</div></div>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":"31 5","pages":"Article 102685"},"PeriodicalIF":1.9,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143692360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Next-generation sequencing assistance in the diagnosis of active tuberculosis following allogeneic hematopoietic stem cell transplantation: A case series","authors":"Dandan Guo ,&nbsp;Jingchao Fan ,&nbsp;Xiaohan Zhang,&nbsp;Shiyu Chen,&nbsp;Xin Du","doi":"10.1016/j.jiac.2025.102683","DOIUrl":"10.1016/j.jiac.2025.102683","url":null,"abstract":"<div><div>Tuberculosis poses a rare but life-threatening complication for patients undergoing hematopoietic stem cell transplantation. In a case series spanning January 2020 to January 2024, we evaluated the application of metagenomic Next-Generation Sequencing in the early diagnosis of tuberculosis in patients following allogeneic hematopoietic stem cell transplantation. We identified 9 cases of post-transplant tuberculosis, predominantly pulmonary, with 1 case of disseminated disease. In early fluid samples from patients with post-transplant active tuberculosis, metagenomic next-generation sequencing detected <em>Mycobacterium tuberculosis</em> complex earlier than conventional tests, enabling rapid diagnosis. In this study, metagenomic next-generation sequencing showed a sensitivity of 66.6 % and specificity of 100 %, higher than TB-DNA and Xpert (55.6 %). Concurrently, among mNGS-positive samples, 4 (44.4 %) were from peripheral blood and 3 (33.3 %) from bronchoalveolar lavage fluid. The combination of metagenomic Next-Generation sequencing and Xpert may enhance the capacity for detecting <em>Mycobacterium tuberculosis</em> complex in extrapulmonary specimens from post-transplant patients. The time from symptom onset to Next-Generation Sequencing positivity was 2–76 days, and from transplantation to TB diagnosis was 30–485 days. Despite some fatalities, the majority of patients completed extended anti-tuberculosis treatment and are under regular follow-up, highlighting the value of Next-Generation Sequencing in diagnosing tuberculosis in this high-risk population.</div></div>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":"31 4","pages":"Article 102683"},"PeriodicalIF":1.9,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143674115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic value of sTREM-1, sCD25, sCD40L and sCD130 in late-onset neonatal sepsis","authors":"Youhong Duan ,&nbsp;Pengyang Li ,&nbsp;Youbao Liang ,&nbsp;Yao Chen","doi":"10.1016/j.jiac.2025.102684","DOIUrl":"10.1016/j.jiac.2025.102684","url":null,"abstract":"<div><h3>Introduction</h3><div>Neonatal sepsis represents a major public health challenge worldwide, presenting serious risks to the health and survival of infants. The identification of novel and efficient serum biomarkers to replace traditional blood cultures is critical for the timely diagnosis and management of this condition. Our objective is to evaluate the diagnostic value of sTREM-1, sCD25, sCD40L, and sCD130 in cases of late-onset neonatal sepsis.</div></div><div><h3>Methods</h3><div>This prospective case-control study comprised 80 infants, 40 suspected of having LOS and 40 serving as the control group. Venous anticoagulated blood was collected to measure sTREM-1, sCD25,sCD40L,sCD130, CRP, and PCT levels.</div></div><div><h3>Results</h3><div>The LOS group exhibited a notably higher occurrence of premature labor, low birth weight, chorioamnionitis, and longer inpatient stays compared to the control group(<em>P</em> &lt; 0.05). CRP, PCT, sTREM-1, and sCD130 were identified as independent predictors of LOS. At the sTREM-1 cutoff value of 42.64 pg/ml, the sensitivity and specificity were 93.20 % and 89.70 %, respectively; at the sCD130 cutoff value of 131165.85 pg/ml, the sensitivity was 91.40 %, and the specificity was 86.20 %. Furthermore, CRP and PCT demonstrated a positive correlation with serum sTREM-1, whereas sCD130 exhibited a negative correlation with both CRP and PCT.</div></div><div><h3>Conclusion</h3><div>Compared to conventional markers,sTREM-1 and sCD130 exhibit higher sensitivity and specificity, making them reliable indicators for diagnosing LOS.</div></div>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":"31 4","pages":"Article 102684"},"PeriodicalIF":1.9,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143674148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ban of colistin livestock feed supplementation decreased the prevalence of colistin-resistant Escherichia coli in Ecuador","authors":"Hoa Thi Thanh Hoang ,&nbsp;Mayumi Yamamoto ,&nbsp;Manuel Calvopina ,&nbsp;Carlos Bastidas-Caldes ,&nbsp;Diep Thi Khong ,&nbsp;Thang Nam Nguyen ,&nbsp;Yoshimasa Yamamoto","doi":"10.1016/j.jiac.2025.102682","DOIUrl":"10.1016/j.jiac.2025.102682","url":null,"abstract":"<div><h3>Objectives</h3><div>In 2019, Ecuador implemented a ban on colistin feed supplementation owing to the increasing prevalence of colistin-resistant bacteria; however, the impact of this ban remains unclear.</div></div><div><h3>Methods</h3><div>In this study, we aimed to elucidate the effects of the 2019 colistin ban by comparing the prevalence of colistin-resistant <em>Escherichia coli</em> in Ecuador with that in Vietnam, where colistin use is still permitted. We isolated colistin-resistant <em>E. coli</em> from the fecal samples of residents and detected mobile colistin resistance (<em>mcr</em>) genes in both the fecal samples and isolates.</div></div><div><h3>Results</h3><div>Prevalence of colistin-resistant <em>E. coli</em> significantly decreased from 80.6 % in 2019 (n = 139) to 4.7 % in 2022 (n = 106) in Ecuador. Meanwhile, colistin-resistant <em>E. coli</em> prevalence only decreased from 84.7 % in 2017 (n = 98) to 62 % in 2024 (n = 50) in Vietnam. Notably, 96.8 % of the colistin-resistant <em>E. coli</em> isolates in Vietnam carried the <em>mcr</em> genes in 2024, whereas only 4.7 % of the isolates in Ecuadorian fecal samples harbored these genes in 2023.</div></div><div><h3>Conclusions</h3><div>Overall, our findings highlight the significant impact of colistin use regulations on the decreased prevalence of colistin-resistant <em>E. coli</em> among Ecuadorian residents.</div></div>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":"31 4","pages":"Article 102682"},"PeriodicalIF":1.9,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143669983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The contribution of metagenomic next-generation sequencing to a diagnosis of gas-producing Fusobacterium-induced septic hip arthritis: A case report","authors":"Shiori Kitaya ,&nbsp;Kazuhiro Horiba ,&nbsp;Tamon Kabata ,&nbsp;Takahiro Iyobe ,&nbsp;Masanori Hashino ,&nbsp;Hiroka Yamazaki ,&nbsp;Yoshinori Takahashi ,&nbsp;Yoshitaka Zaimoku ,&nbsp;Megumi Oshima ,&nbsp;Hajime Kanamori","doi":"10.1016/j.jiac.2025.102681","DOIUrl":"10.1016/j.jiac.2025.102681","url":null,"abstract":"<div><div>Pyogenic arthritis with gas gangrene triggered by intra-articular steroid injections can occasionally result in fatal complications. <em>Clostridium perfringens</em> is typically the causative pathogen, with infections caused by <em>Fusobacterium</em> species being relatively rare. <em>Fusobacterium</em> species are known to cause pyogenic infections, but due to their extreme sensitivity to oxygen, they can be difficult to detect with traditional culture methods. Recently, metagenomic next-generation sequencing (mNGS) has gained attention as an alternative diagnostic tool to traditional culture, enabling rapid identification of causative pathogens in infectious diseases, including pyogenic arthritis. Its use is illustrated in the following case report, which demonstrates the diagnostic utility of mNGS in pyogenic arthritis with gas gangrene triggered by an intra-articular steroid injection. Using mNGS as a complement to conventional culture testing allows for a more precise narrowing-down of causative pathogens, enabling targeted therapy and improving patient outcomes. This approach may also help reduce the use of broad-spectrum antibiotics and prevent the emergence of antibiotic-resistant bacteria.</div></div>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":"31 4","pages":"Article 102681"},"PeriodicalIF":1.9,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143639728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An evaluation of the modified carbapenem inactivation method (mCIM) in conjunction with EDTA or sodium mercaptoacetate, for detecting metallo β-lactamase production for Aeromonas species harboring blaCphA","authors":"Kohei Uechi ,&nbsp;Naoya Nishiyama ,&nbsp;Wakako Arakaki ,&nbsp;Ami Nakano ,&nbsp;Ayumi Uechi ,&nbsp;Tatsuya Nakamura ,&nbsp;Kazuko Yamamoto ,&nbsp;Shiro Maeda","doi":"10.1016/j.jiac.2025.102678","DOIUrl":"10.1016/j.jiac.2025.102678","url":null,"abstract":"<div><div>Several <em>Aeromonas</em> species, including <em>Aeromonas hydrophila</em>, have been known to produce CphA, a chromosomal metallo β-lactamase (MBL). We aimed to evaluate the clinical usefulness of modified carbapenem inactivation method (mCIM) in conjunction with EDTA (eCIM) or sodium mercaptoacetate (SMA-mCIM) for MBL-producing <em>Aeromonas</em> species.</div><div>Fifty-six clinical isolates of <em>Aeromonas</em> species stored at the University of the Ryukyus Hospital were used in this study. The antimicrobial susceptibility testing was performed using a VITEK®2 AST-N404 card (bioMerieux, Marcy-l'Etoile, France) and the results were interpreted according to the CLSI guideline M45 3rd edition. The carbapenemase genes, namely <em>bla</em>_GES, <em>bla</em>_IMP, <em>bla</em>_KPC, <em>bla</em>_NDM, <em>bla</em>_OXA-48-like, <em>bla</em>_VIM, and <em>bla</em>_CphA, were detected by PCR. The production of carbapenemase was evaluated using the mCIM and the differentiation of MBL was eCIM and SMA-mCIM.</div><div>The resistance rates to imipenem and meropenem were 21.4 % (12/56) and 32.1 % (18/56), respectively. The mCIM showed a sensitivity of 100 % (33/33 <em>bla</em>_CphA positive isolates) and a specificity of 95.7 % (22/23 <em>bla</em>_CphA negative isolates) for the tested isolates. Among the 33 mCIM-positive isolates, 29 (87.9 %) for eCIM, and 6 (18.2 %) for SMA-mCIM were judged as MBL positive, respectively.</div><div>It is suggested that the mCIM in conjunction with EDTA is useful for detecting MBL production in <em>Aeromonas</em> species harboring <em>bla</em>_CphA.</div></div>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":"31 4","pages":"Article 102678"},"PeriodicalIF":1.9,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143624952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emergence of high-level penicillin-resistant Neisseria meningitidis harboring ROB-1-type β-lactamase gene in Japan","authors":"Hideyuki Takahashi ,&nbsp;Yuki Ohama ,&nbsp;Kazuhiro Horiba ,&nbsp;Munehisa Fukusumi ,&nbsp;Tomimasa Sunagawa ,&nbsp;Tsukasa Ariyoshi ,&nbsp;Mayako Koide ,&nbsp;Ken Shimuta ,&nbsp;Ryoichi Saito ,&nbsp;Yukihiro Akeda","doi":"10.1016/j.jiac.2025.102679","DOIUrl":"10.1016/j.jiac.2025.102679","url":null,"abstract":"<div><div>While antimicrobial resistance in <em>Neisseria meningitidis</em>, the causative agent for invasive meningococcal disease (IMD), is rare, some meningococcal isolates in Japan were resistant to ciprofloxacin and penicillin (PCG). Among 290 meningococci isolated from 2003 to 2020 in Japan, four PCG resistant (PCG^R) meningococci were found but showed the minimum inhibitory concentration (MIC) with 0.5 μg/mL at a maximum due to mutation in <em>penA</em> gene that encodes penicillin-binding protein 2. However, we herein report that PCG^R meningococci harboring the ROB-1-type β-lactamase gene (<em>bla</em>_ROB-1) with PCG MIC of 32 μg/mL were isolated in Japan from 2 independent IMD patients at Tokyo in June, and at Shiga in December in 2024. The both isolates were also resistant to another β-lactams, ampicillin and amoxicillin. The PCG^R meningococci with <em>bla</em>_ROB-1, which was genetically classified in sequence type (ST)-3587, was firstly identified in France in 2018 and isolated only in European and American countries until 2024. Phylogenetic analysis with whole genome sequencing revealed that the two Japanese <em>N. meningitidis</em> isolates were not genetically identical and that they were not identical to other ST-3057 meningococci isolated in western countries. The emergence of the <em>bla</em>_ROB-1 positive meningococci in Japan would warn medical risk that β-lactams such as PCG and amoxicillin are not always applicable to IMD treatment and prevention in Japan.</div></div>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":"31 4","pages":"Article 102679"},"PeriodicalIF":1.9,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143624966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence and risk factors of COVID-19-associated pulmonary aspergillosis in severe cases: A single-center study from Japan","authors":"Kengo Kawamoto ,&nbsp;Waki Imoto ,&nbsp;Yoshihiro Kimura ,&nbsp;Shigeki Kakuno ,&nbsp;Wataru Shibata ,&nbsp;Yuka Myodo ,&nbsp;Tetsuro Nishimura ,&nbsp;Shoichi Ehara ,&nbsp;Hiromichi Fujii ,&nbsp;Yasumitsu Mizobata ,&nbsp;Toshihiko Shibata ,&nbsp;Hiroshi Kakeya","doi":"10.1016/j.jiac.2025.102676","DOIUrl":"10.1016/j.jiac.2025.102676","url":null,"abstract":"<div><h3>Objective</h3><div>Coronavirus disease 2019 (COVID-19)-associated pulmonary aspergillosis (CAPA) is a serious complication in patients with severe COVID-19. This study investigated the incidence and risk factors for CAPA in patients with severe COVID-19 at Osaka Public University Hospital from April 2020 to November 2021.</div></div><div><h3>Methods</h3><div>This retrospective study involved patients with CAPA patients requiring invasive ventilation who were diagnosed according to the European Confederation of Medical Mycology and the International Society of Human and Animal Mycology criteria. Patients were classified into the CAPA and non-CAPA groups. Data collected included age, sex, body mass index, smoking history, underlying disease, length of hospital stay, steroid and other drug use, extracorporeal membrane oxygenation use, and outcome. Univariate analysis was used to identify risk factors associated with CAPA.</div></div><div><h3>Results</h3><div>Of the 256 COVID-19 patients, 187 required invasive ventilation, and eight were diagnosed with CAPA. The incidence of CAPA among COVID-19 patients requiring ventilator management was 4.28 %. Tracheostomy was performed in seven patients, and <em>Aspergillus</em> spp. was detected in six, of whom four were confirmed to have <em>A. fumigatus</em>. CAPA mortality was high, with six of eight patients dying. Univariate analysis showed COPD (P = 0.04) and chronic liver disease (P = 0.04) as common comorbidities. β-D-glucan positivity, tracheostomy, prolonged hospitalization, prolonged steroid use, and death (P &lt; 0.01) were more prevalent in the CAPA group.</div></div><div><h3>Conclusions</h3><div>When bronchoscopy is unfeasible, early diagnosis using serum <em>Aspergillus</em> antigen measurement and imaging is essential, particularly for patients with COPD, liver disease, or risk factors like prolonged hospitalization or steroid use post-COVID-19 treatment.</div></div>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":"31 4","pages":"Article 102676"},"PeriodicalIF":1.9,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143586056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Central venous access Port–Related blood stream infection caused by Cyberlindnera fabianii: A case report and literature review","authors":"Koichi Kawasaki ,&nbsp;Toyomitsu Sawai ,&nbsp;Yudai Inadomi ,&nbsp;Shun Morimitsu ,&nbsp;Tomonari Ikeda ,&nbsp;Sumako Yoshioka ,&nbsp;Nobuko Matsuo ,&nbsp;Junichi Kadota ,&nbsp;Katsunori Yanagihara ,&nbsp;Hiroshi Mukae","doi":"10.1016/j.jiac.2025.102662","DOIUrl":"10.1016/j.jiac.2025.102662","url":null,"abstract":"<div><div><em>Cyberlindnera fabianii</em>, an ascomycetous yeast, is a rare human pathogen. Here, we describe the first reported case of central venous (CV) access port–related blood-stream infection caused by <em>C. fabianii</em>. An 80-year-old Asian man presented to our department with a mass in the pancreas. A diagnosis of pancreatic cancer (cT4N0M0, cStage III) was made. A catheter with CV access port was inserted, and anticancer chemotherapy and radiotherapy was initiated. One year after the first visit, he was urgently admitted to our hospital due to recurrent hematemesis. On day 37, organism cultures of the blood and catheter tip were positive for <em>Candida pelliculosa</em> by the BD PHOENIX™ 100 system. On the basis of these findings, CV port–related blood-stream infection caused by <em>C</em>. <em>pelliculosa</em> was diagnosed, and treatment with micafungin (MCFG) was initiated. On day 51, the blood culture converted to negative. On day 65, MCFG was stopped. The cultured strain was sent to reference laboratory where <em>Cyberlindnera fabianii</em> was identified by MALDI-TOF mass spectrometry and direct sequencing of the internally transcribed spacer region. The present case report describes the first known case of CV access port–related blood-stream infection caused by <em>C. fabianii</em>. MCFG was successfully used to treat the fungemia caused by <em>C. fabianii</em>. Although the incidence of uncommon yeast species causing human infections has gradually increased in recent years, conventional biochemical methods may offer limited usefulness for identifying these rare organisms. Accordingly, MALDI-TOF mass spectrometry or molecular assays may be required to identify these uncommon fungal species.</div></div>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":"31 4","pages":"Article 102662"},"PeriodicalIF":1.9,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143586051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}